Updated Therapeutic Area GPCR Panels
Tanso Biosciences, Inc. is pleased to announce an update to its FlexPanel48 Therapeutic Area Panels, leveraging the latest disease–gene association data to help accelerate drug discovery research. To date, Tanso Biosciences has provided panels consisting of 48 GPCRs per therapeutic area, selected for their relevance across 13 therapeutic areas. These panels have been widely used for target evaluation and compound screening in the early stages of drug discovery. We reselected the 48 receptors for each therapeutic area based on the latest version of the DISGENET database, which accommodates more than two million disease–gene association records. By using disease relevance scores, we identified the GPCRs most closely associated with each disease, making the panels more reflective of […]
Tanso Bio Secures US Patent for GPCR Assay Technology
Tanso Biosciences is proud to announce that the United States Patent and Trademark Office (USPTO) has officially granted a patent (Patent No. US-12247244-B2) for its innovation to perform functional assays for G protein-coupled receptors (GPCRs). This patent protects Tanso Biosciences' proprietary assay platform and reinforces the company's dedication to advancing drug discovery. GPCRs play a vital role in numerous physiological processes and are among the most significant classes of drug targets in modern pharmacology. Tanso Biosciences' newly patented technology offers a cutting-edge, highly reliable approach to assessing GPCR functionality, enabling more efficient and accurate drug screening and development.
Metformin's Anti-Tumor Mechanism Uncovered by Using Tanso Bio's Assay Platform
We are excited to announce that researchers at the Institute for Molecular and Cellular Regulation of Gunma University, in collaboration with Tanso Biosciences, have discovered that metformin, a medication used to treat type 2 diabetes, may suppress tumors by inhibiting lysophosphatidic acid receptors. This study utilized Tanso Biosciences' GPCR functional assay platform to thoroughly assess metformin's agonistic and antagonistic potency against 200 non-orphan GPCRs. The findings were published in the journal Diabetes Research and Clinical Practice. More details can be found here.


